
Frankie Ann Holmes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research, 2015, 21, 4305-4311.	7.0	51
2	Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Clinical Cancer Research, 2021, 27, 807-818.	7.0	34
3	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 6149-6157.	7.0	29
4	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. Npj Breast Cancer, 2019, 5, 36.	5.2	9
5	Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC) Journal of Clinical Oncology, 2012, 30, 1017-1017.	1.6	3
6	Fiveâ€year results of a phase <scp>II</scp> trial of preoperative 5â€fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (<scp>wTX</scp>) (with trastuzumab in) Tj ETQq0 C cancer. Cancer Medicine, 2018, 7, 2288-2298.	0 rgBT /C	verlock 10 Tf
7	Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. Cancer Research, 2021, 81, PD3-03-PD3-03.	0.9	2
8	Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. Current Problems in Cancer Case Reports, 2020, 2, 100033.	0.1	1
9	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses Journal of Clinical Oncology, 2012, 30, 547-547.	1.6	1
10	Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. Cancer Research, 2022, 82, P2-13-21-P2-13-21.	0.9	1
11	Scalp cooling alopecia prevention trial (SCALP) Journal of Clinical Oncology, 2014, 32, TPS9660-TPS9660.	1.6	Ο
12	Evidence of <i>PIK3CA</i> and <i>TP53</i> co-mutation in breast cancer identification on next-generation sequencing (NGS) of <i>ERBB2</i> (<i>HER2</i>)-amplified residual disease following preoperative anti-HER2 therapy Journal of Clinical Oncology, 2014, 32, 625-625.	1.6	0
13	HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL) Journal of Clinical Oncology, 2015, 33, 621-621.	1.6	0
14	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer Journal of Clinical Oncology, 2016, 34, TPS10144-TPS10144.	1.6	0